However, the absence or weak expression of TRK cannot rule out the NTRK fusion uterine sarcoma due to the poor sensitivity and specificity of IHC staining of TRK, which should be verified by molecular testing if necessary. The gene discussed is TPM3; the disease is uterine corpus sarcoma.